Biotech | March 11, 2022
First-in-human trial in US for Gan & Lee type 2 diabetes drug
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Subscribe To Our Newsletter & Stay Updated
